Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
1(14%)
Results Posted
133%(4 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_1
2
29%
Ph phase_2
3
43%
Ph phase_3
1
14%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Terminated2
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
Phase 31 (16.7%)

Trials by Status

unknown114%
active_not_recruiting114%
completed343%
terminated229%

Recent Activity

1 active trials
Showing 5 of 7
completedphase_3

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

NCT04442048
active_not_recruitingphase_2

Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

NCT05118724
terminatedphase_1

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

NCT03009058
completedphase_2

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

NCT03711188
terminatedphase_1

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

NCT01559818
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04442048Phase 3

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

Completed
NCT05118724Phase 2

Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

Active Not Recruiting
NCT03009058Phase 1

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Terminated
NCT03711188Phase 2

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

Completed
NCT01559818Phase 1

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

Terminated
NCT01303172Phase 2

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Completed
NCT04137822

Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

Unknown

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7